Clarametyx Biosciences: $33 Million Secured To Advance Anti-Biofilm Biologics For Bacterial Infections
By Annie Baker ● Jan 6, 2024
Clarametyx Biosciences - a clinical-stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms – recently announced the successful completion of a $33 million Series A round. The Series A financing was led by the Ohio Innovation Fund, with participation from current investors Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors, and 1776 Fund.